Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia

Acquired Hemophilia A (AHA) is a rare disease caused by anti-factor VIII autoantibodies. It is usually characterized by clinically significant bleeding at the onset and requires prompt hemostatic and immunosuppressive therapies. Due to its rarity and the lack of randomized trials, its treatment is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazziotta, Francesco, Cecconi, Nadia, Iovino, Lorenzo, Cervetti, Giulia, Petrini, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2019
Materias:
Allergy/Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822901/
https://www.ncbi.nlm.nih.gov/pubmed/31700733
http://dx.doi.org/10.7759/cureus.5630
_version_ 1783464433322819584
author Mazziotta, Francesco
Cecconi, Nadia
Iovino, Lorenzo
Cervetti, Giulia
Petrini, Mario
author_facet Mazziotta, Francesco
Cecconi, Nadia
Iovino, Lorenzo
Cervetti, Giulia
Petrini, Mario
author_sort Mazziotta, Francesco
collection PubMed
description Acquired Hemophilia A (AHA) is a rare disease caused by anti-factor VIII autoantibodies. It is usually characterized by clinically significant bleeding at the onset and requires prompt hemostatic and immunosuppressive therapies. Due to its rarity and the lack of randomized trials, its treatment is a great challenge, especially in the relapse/refractory setting. This report presents the case of a patient diagnosed with chronic lymphocytic leukemia who developed a steroid-resistant AHA, successfully managed with aggressive immunosuppressive therapy.
format Online
Article
Text
id pubmed-6822901
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-68229012019-11-07 Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia Mazziotta, Francesco Cecconi, Nadia Iovino, Lorenzo Cervetti, Giulia Petrini, Mario Cureus Allergy/Immunology Acquired Hemophilia A (AHA) is a rare disease caused by anti-factor VIII autoantibodies. It is usually characterized by clinically significant bleeding at the onset and requires prompt hemostatic and immunosuppressive therapies. Due to its rarity and the lack of randomized trials, its treatment is a great challenge, especially in the relapse/refractory setting. This report presents the case of a patient diagnosed with chronic lymphocytic leukemia who developed a steroid-resistant AHA, successfully managed with aggressive immunosuppressive therapy. Cureus 2019-09-12 /pmc/articles/PMC6822901/ /pubmed/31700733 http://dx.doi.org/10.7759/cureus.5630 Text en Copyright © 2019, Mazziotta et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Allergy/Immunology
Mazziotta, Francesco
Cecconi, Nadia
Iovino, Lorenzo
Cervetti, Giulia
Petrini, Mario
Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia
title Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia
title_full Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia
title_fullStr Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia
title_full_unstemmed Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia
title_short Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia
title_sort safety and efficacy of rituximab and cyclophosphamide in a case of resistant acquired hemophilia a in course of chronic lymphocytic leukemia
topic Allergy/Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822901/
https://www.ncbi.nlm.nih.gov/pubmed/31700733
http://dx.doi.org/10.7759/cureus.5630
work_keys_str_mv AT mazziottafrancesco safetyandefficacyofrituximabandcyclophosphamideinacaseofresistantacquiredhemophiliaaincourseofchroniclymphocyticleukemia
AT cecconinadia safetyandefficacyofrituximabandcyclophosphamideinacaseofresistantacquiredhemophiliaaincourseofchroniclymphocyticleukemia
AT iovinolorenzo safetyandefficacyofrituximabandcyclophosphamideinacaseofresistantacquiredhemophiliaaincourseofchroniclymphocyticleukemia
AT cervettigiulia safetyandefficacyofrituximabandcyclophosphamideinacaseofresistantacquiredhemophiliaaincourseofchroniclymphocyticleukemia
AT petrinimario safetyandefficacyofrituximabandcyclophosphamideinacaseofresistantacquiredhemophiliaaincourseofchroniclymphocyticleukemia

Ejemplares similares